Diabetes mellitus and gastric emptying: Questions and issues in clinical practice

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 6, 2009, Pages 502-514

  Samsom, Melvin ^a   Bharucha, Adil ^b   Gerich, John E ^c   Herrmann, Kathrin ^d   Limmer, Jörg ^d   Linke, Rainer ^e,h   Maggs, David ^d   Schirra, Jörg ^f   Vella, Adrian ^g   Wörle, Hans Jürgen ^f,i   Göke, Burkhard ^f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d AMYLIN PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Delayed gastric emptying; Gastroparesis; Glucose; T1DM; T2DM

Indexed keywords

ANTIEMETIC AGENT; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; EXENDIN 4; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIRAGLUTIDE; METOCLOPRAMIDE; PLACEBO; PRAMLINTIDE;

ABDOMINAL PAIN; BREATH ANALYSIS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG INDUCED HEADACHE; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; STOMACH EMPTYING; STOMACH PARESIS; STOMACH SCINTISCANNING; VOMITING;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; GASTRIC EMPTYING; GASTROPARESIS; HUMANS;

EID: 70350578556     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.974     Document Type: Review

References (164)

1. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 2001; 161(16): 1989-1996. (Pubitemid 32816562)
2. Ricci JA, Siddique R, Stewart WF, Sandler RS, Sloan S, Farup CE. Upper gastrointestinal symptoms in a U.S. national sample of adults with diabetes. Scand J Gastroenterol 2000; 35(2): 152-159. (Pubitemid 30216583)
3. Samsom M, Roelofs JM, Akkermans LM, van Berge Henegouwen GP, Smout AJ. Proximal gastric motor activity in response to a liquid meal in type I diabetes mellitus with autonomic neuropathy. Dig Dis Sci 1998; 43(3): 491-496. (Pubitemid 28155568)
4. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994; 37(6): 543-551. (Pubitemid 24162424)
5. Horowitz M, Wishart JM, Jones KL, Hebbard GS. Gastric emptying in diabetes: an overview. Diabet Med 1996; 13(9): Suppl 5: S16-S22.
6. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24(7): 1264-1269. (Pubitemid 33716409)
7. Kong MF, Horowitz M. Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Clin Geriatr Med 1999; 15(2): 321-338. (Pubitemid 29235187)
8. Samsom M, Vermeijden JR, Smout AJ, et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care 2003; 26(11): 3116-3122. (Pubitemid 37339507)
9. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18(4): 229-234.
10. Janatuinen E, Pikkarainen P, Laakso M, Pyorala K. Gastrointestinal symptoms in middle-aged diabetic patients. Scand J Gastroenterol 1993; 28(5): 427-432. (Pubitemid 23116595)
11. Maleki D, Locke GR III, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000; 160(18): 2808-2816. (Pubitemid 30743859)
12. Bharucha AE, Camilleri M, Low PA, Zinsmeister AR. Autonomic dysfunction in gastrointestinal motility disorders. Gut 1993; 34(3): 397-401. (Pubitemid 23080269)
13. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24(2): 371-381. (Pubitemid 32119141)
14. Samsom M, Akkermans LM, Jebbink RJ, van IH, Vanberge- Henegouwen GP, Smout AJ. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. Gut 1997; 40(5): 641-646. (Pubitemid 27278333)
15. Schvarcz E, Palmer M, Ingberg CM, Aman J, Berne C. Increased prevalence of upper gastrointestinal symptoms in long-term type 1 diabetes mellitus. Diabet Med 1996; 13(5): 478-481. (Pubitemid 26173434)
16. Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988; 94(3): 739-744. (Pubitemid 18073537)
17. Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97(1): 92-103. (Pubitemid 26021698)
18. Schvarcz E, Palmer M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabet Med 1993; 10(7): 660-663. (Pubitemid 23246786)
19. Kong MF, King P, Macdonald IA, et al. Euglycaemic hyperinsulinaemia does not affect gastric emptying in type I and type II diabetes mellitus. Diabetologia 1999; 42(3): 365-372. (Pubitemid 29111445)
20. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying in patients with early non-insulin-dependent diabetes mellitus. N Engl JMed 1991; 324(2): 130-131.
21. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA.Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109(3): 755-765.
22. Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol 1987; 82(1): 29-35. (Pubitemid 17231680)
23. Lyrenas EB, Olsson EH, Arvidsson UC, Orn TJ, Spjuth JH. Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes. Relationship to postprandial blood glucose concentrations. Diabetes Care 1997; 20(3): 413-418.
24. Nowak TV, Johnson CP, Kalbfleisch JH, et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 1995; 37(1): 23-29.
25. Wegener M, Borsch G, Schaffstein J, Luerweg C, Leverkus F. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis 1990; 8(1): 23-36.
26. Ziegler D, Schadewaldt P, Pour MA, et al. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996; 39(7): 823-830. (Pubitemid 26228112)
27. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996; 19(5): 468-471. (Pubitemid 26143749)
28. Ceriello A, Quagliaro L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25(8): 1439-1443. (Pubitemid 41071158)
29. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004; 53(3): 701-710. (Pubitemid 38270640)
30. Charpentier G, Riveline JP, Dardari D, Varroud-Vial M. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated? Drugs 2006; 66(3): 273-286. (Pubitemid 46291764)
31. Eschwege E, Balkau B. Hyperglycaemia: link to excess mortality. Int J Clin Pract Suppl 2001; (123): 3-6.
32. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110(2): 214-219. (Pubitemid 38924590)
33. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106(16): 2067-2072. (Pubitemid 35192812)
34. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36(11-12): 867-876. (Pubitemid 40115912)
35. Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006; 28(1-2): 96-108.
36. Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7(8): 1055-1064. (Pubitemid 43949943)
37. Combettes MM. GLP-1 and type 2 diabetes: physiology and new clinical advances. Curr Opin Pharmacol 2006; 6(6): 598-605. (Pubitemid 44660946)
38. Levy JC. Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes. Diabet Med 2006; 23(Suppl 1): 14-19.
39. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7(14): 1353-1373. (Pubitemid 32798815)
40. Collins PJ, Horowitz M, Cook DJ, Harding PE, Shearman DJ. Gastric emptying in normal subjects - a reproducible technique using a single scintillation camera and computer system. Gut 1983; 24(12): 1117-1125. (Pubitemid 14205812)
41. Moore JG, Christian PE, Coleman RE. Gastric emptying of varying meal weight and composition in man. Evaluation by dual liquid- and solid-phase isotopic method. Dig Dis Sci 1981; 26(1): 16-22.
42. Horowitz M, Edelbroeck MAI, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993; 36: 857-862. (Pubitemid 23248159)
43. Pilichiewicz AN, Chaikomin R, Brennan IM, et al. Loaddependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 2007; 293(3): E743-E753. (Pubitemid 47358986)
44. Blair EH, Wing RR, Wald A. The effect of laboratory stressors on glycemic control and gastrointestinal transit time. Psychosom Med 1991; 53(2): 133-143.
45. Hunt JN, Knox MT. Control of gastric emptying. Am J Dig Dis 1968; 13(4): 372-375.
46. Kelley D, Mitrakou A, Marsh H, et al. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin Invest 1988; 81(5): 1563-1571. (Pubitemid 18131625)
47. Delgado-Aros S, Vella A, Camilleri M, et al. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil 2003; 15(4): 435-443. (Pubitemid 36876259)
48. Horowitz M, Dent J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillieres Clin Gastroenterol 1991; 5(2): 371-407.
49. Chaikomin R, Rayner CK, Jones KL, Horowitz M. Upper gastrointestinal function and glycemic control in diabetes mellitus. World J Gastroenterol 2006; 12(35): 5611-5621. (Pubitemid 44594034)
50. Meyer C, Gerich JE. Role of the kidney in hyperglycemia in type 2 diabetes. Curr Diab Rep 2002; 2(3): 237-241.
51. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA. Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest 1984; 74(3): 985-991. (Pubitemid 14031038)
52. Anderson JW, O'Neal DS, Riddell-Mason S, Floore TL, Dillon DW, Oeltgen PR. Postprandial serum glucose, insulin, and lipoprotein responses to high- and low-fiber diets. Metabolism 1995; 44: 848-854.
53. Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 1994; 271: 1421-1428. (Pubitemid 24986683)
54. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26(3): 881-885. (Pubitemid 36929359)
55. Lingenfelser T, Sun W, Hebbard GS, Dent J, Horowitz M. Effects of duodenal distension on antropyloroduodenal pressures and perception are modified by hyperglycemia. Am J Physiol 1999; 276(3 Pt 1): G711-G718. (Pubitemid 29157437)
56. Hebbard GS, Sun WM, Dent J, Horowitz M. Hyperglycaemia affects proximal gastric motor and sensory function in normal subjects. Eur J Gastroenterol Hepatol 1996; 8(3): 211-217. (Pubitemid 26132096)
57. Gerich JE. Pathogenesis and treatment of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM). Horm Metab Res 1996; 28(9): 404-412. (Pubitemid 26343729)
58. Russo A, Stevens JE, Chen R, et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005; 90(8): 4489-4495. (Pubitemid 41159331)
59. Lysy J, Israeli E, Strauss-Liviatan N, Goldin E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients. Neurogastroenterol Motil 2006; 18(6): 433-440. (Pubitemid 43742557)
60. Horowitz M, Jones KL, Rayner CK, Read NW. 'Gastric' hypoglycaemia - an important concept in diabetes management. Neurogastroenterol Motil 2006; 18(6): 405-407. (Pubitemid 43742553)
61. Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113(1): 60-66. (Pubitemid 27281758)
62. Woerle HJ, Albrecht M, Linke R, et al. Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide (IAPP). Diabetes Care 2008; 31(12): 2325-2331.
63. Samsom M, Salet GA, Roelofs JM, Akkermans LM, Vanberge-Henegouwen GP, Smout AJ. Compliance of the proximal stomach and dyspeptic symptoms in patients with type I diabetes mellitus. Dig Dis Sci 1995; 40(9): 2037-2042.
64. Darwiche G, Almer LO, Bjorgell O, Cederholm C, Nilsson P. Delayed gastric emptying rate in Type 1 diabetics with cardiac autonomic neuropathy. J Diabetes Complications 2001; 15(3): 128-134. (Pubitemid 32453169)
65. Schvarcz E, Palmer M, Aman J, Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabetes Care 1995; 18(5): 674-676.
66. Gedulin BR, Young AA. Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes 1998; 47(1): 93-97.
67. Bertin E, Schneider N, Abdelli N, et al. Gastric emptying is accelerated in obese type 2 diabetic patients without autonomic neuropathy. Diabetes Metab 2001; 27(3): 357-364. (Pubitemid 32625389)
68. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med 1992; 33(8): 1496-1500.
69. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32(3): 151-159. (Pubitemid 19117093)
70. Benini L, Sembenini C, Heading RC, et al. Simultaneous measurement of gastric emptying of a solid meal by ultrasound and by scintigraphy. Am J Gastroenterol 1999; 94(10): 2861-2865. (Pubitemid 29482747)
71. Feinle C, Kunz P, Boesiger P, Fried M, Schwizer W. Scintigraphic validation of a magnetic resonance imaging method to study gastric emptying of a solid meal in humans. Gut 1999; 44(1): 106-111. (Pubitemid 29143289)
72. Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104(6): 1640-1647.
73. Schwizer W, Maecke H, Fried M. Measurement of gastric emptying by magnetic resonance imaging in humans. Gastroenterology 1992; 103(2): 369-376.
74. Maggs D, Macdonald I, Nauck MA. Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. Diabetes Obes Metab 2008; 10(1): 18-33. (Pubitemid 350302429)
75. Heddle R, Dent J, Read NW, et al. Antropyloroduodenal motor responses to intraduodenal lipid infusion in healthy volunteers. Am J Physiol 1988; 254(5 Pt 1): G671-G679. (Pubitemid 18137198)
76. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127(5): 1592-1622. (Pubitemid 39457783)
77. Cotroneo P, Grattagliano A, Rapaccini GL, et al. Gastric emptying rate and hormonal response in type II diabetics. Diabetes Res 1991; 17(2): 99-104.
78. Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000; 106(3): 373-384. (Pubitemid 30655637)
79. Iwasaki H, Kajimura M, Osawa S, et al. A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J Gastroenterol 2006; 41(11): 1076-1087. (Pubitemid 44896722)
80. Gangula PR, Maner WL, Micci MA, Garfield RE, Pasricha PJ. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am J Physiol Gastrointest Liver Physiol 2007; 292(3): G725-G733.
81. Jones KL, Horowitz M, Berry M, Wishart JM, Guha S. Blood glucose concentration influences postprandial fullness in IDDM. Diabetes Care 1997; 20(7): 1141-1146. (Pubitemid 27274278)
82. Kong MF, Macdonald IA, Tattersall RB. Gastric emptying in diabetes. Diabet Med 1996; 13(2): 112-119.
83. O'Donovan D, Feinle-Bisset C, Jones K, Horowitz M. Idiopathic and diabetic gastroparesis. Curr Treat Options Gastroenterol 2003; 6(4): 299-309.
84. Webb WW, Fogel RP. Gastroparesis: current management. Compr Ther 1995; 21(12): 741-745.
85. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26(5): 1553-1579.
86. Shen B, Soffer EE. A review of diabetic gastropathy. Compr Ther 2001; 27(1): 56-59.
87. Zitomer BR, Gramm HF, Kozak GP. Gastric neuropathy in diabetes mellitus: clinical and radiologic observations. Metabolism 1968; 17(3): 199-211.
88. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127(5): 1589-1591. (Pubitemid 39457782)
89. Mariani G, Boni G, Barreca M, et al. Radionuclide gastroesophageal motor studies. J Nucl Med 2004; 45(6): 1004-1028.
90. Abell TL, Camilleri M, Donohoe K, et al.; American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol 2008; 36(1): 44-54.
91. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000; 95(6): 1456-1462. (Pubitemid 30396302)
92. Tatsch K, Voderholzer WA, Weiss MJ, Schrottle W, Hahn K. Reappraisal of quantitative esophageal scintigraphy by optimizing resultswith ROC analyses. J Nucl Med 1996; 37(11): 1799-1805. (Pubitemid 26378365)
93. Tougas G, Chen Y, Coates G, et al. Standardization of a simplified scintigraphic methodology for the assessment of gastric emptying in a multicenter setting. Am J Gastroenterol 2000; 95(1): 78-86. (Pubitemid 30041539)
94. Ziessman HA, Fahey FH, Atkins FB, Tall J. Standardization and quantification of radionuclide solid gastric-emptying studies. J Nucl Med 2004; 45(5): 760-764. (Pubitemid 47618553)
95. Zahn A, Langhans CD, Hoffner S, et al. Measurement of gastric emptying by 13C-octanoic acid breath test versus scintigraphy in diabetics. Z Gastroenterol 2003; 41(5): 383-390. (Pubitemid 36686904)
96. Lee JS, Camilleri M, Zinsmeister AR, et al. Toward office-based measurement of gastric emptying in symptomatic diabetics using [13C]octanoic acid breath test. Am J Gastroenterol 2000; 95(10): 2751-2761. (Pubitemid 30783196)
97. Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 2002; 14(2): 123-131. (Pubitemid 34451212)
98. Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol 2008; 6(6): 635-643.
99. Kim DY, Myung SJ, Camilleri M. Novel testing of human gastric motor and sensory functions: rationale, methods, and potential applications in clinical practice. Am J Gastroenterol 2000; 95(12): 3365-3373.
100. Berstad A, Hausken T, Gilja OH, Hveem K, Nesje LB, Odegaard S. Ultrasonography of the human stomach. Scand J Gastroenterol Suppl 1996; 220: 75-82.
101. Hveem K, Jones KL, Chatterton BE, Horowitz M. Scintigraphic measurement of gastric emptying and ultrasonographic assessment of antral area: relation to appetite. Gut 1996; 38(6): 816-821. (Pubitemid 26231762)
102. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther 2008; 27(2): 186-196. (Pubitemid 350256610)
103. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl JMed 1990; 322(15): 1028-1031. (Pubitemid 20146660)
104. DiBaise JK, Park FL, Lyden E, Brand RE, Brand RM. Effects of low doses of erythromycin on the 13C Spirulina platensis gastric emptying breath test and electrogastrogram: a controlled study in healthy volunteers. Am J Gastroenterol 2001; 96(7): 2041-2050. (Pubitemid 32660895)
105. Ishii M, Nakamura T, Kasai F, Baba T, Takebe K. Erythromycin derivative improves gastric emptying and insulin requirement in diabetic patients with gastroparesis. Diabetes Care 1997; 20(7): 1134-1137. (Pubitemid 27274276)
106. Gonlachanvit S, Hsu CW, Boden GH, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci 2003; 48(3): 488-497. (Pubitemid 36324155)
107. Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127: 1592-1622. (Pubitemid 39457783)
108. Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005; 54(12): 1693-1698. (Pubitemid 41697666)
109. Castillo EJ, gado-Aros S, Camilleri M, et al. Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2004; 287(2): G363-G369.
110. Asai S, Katabami T, Obi N, et al. No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. Endocr J 2009; 56(1): 79-87.
111. Mearadji B, Straathof JW, Lamers CB, Masclee AA. Effect of gastrin on proximal gastric motor function in humans. Neurogastroenterol Motil 1999; 11(6): 449-455. (Pubitemid 28289525)
112. Park MI, Camilleri M. Gastroparesis: clinical update. Am J Gastroenterol 2006; 101(5): 1129-1139.
113. Ali T, Hasan M, Hamadani M, Harty RF. Gastroparesis. South Med J 2007; 100(3): 281-286.
114. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-986. (Pubitemid 23307905)
115. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
116. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643-2653. (Pubitemid 41817713)
117. Forst T, Forst S, Strunk K, et al. Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. J Diabetes Complications 2005; 19(3): 128-132. (Pubitemid 40615542)
118. Heine RJ, Balkau B, Ceriello A, Del PS, Horton ES, Taskinen MR. What does postprandial hyperglycaemia mean?. Diabet Med 2004; 21(3): 208-213. (Pubitemid 38299612)
119. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46(Suppl 1): M9-M16. (Pubitemid 36543098)
120. Gentilcore D, Chaikomin R, Jones KL, et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 2006; 91(6): 2062-2067. (Pubitemid 43854982)
121. Ceriello A, Piconi L, Quagliaro L, et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005; 28(3): 632-637. (Pubitemid 40315324)
122. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27(11): 2628-2635. (Pubitemid 39441462)
123. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092-1100. (Pubitemid 40616618)
124. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): 1083-1091. (Pubitemid 40616617)
125. Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998; 41(5): 577-583. (Pubitemid 28206829)
126. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol 2000; 278(6): G946-G951. (Pubitemid 30439174)
127. Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 2002; 14(2): 123-131. (Pubitemid 34451212)
128. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995; 38(6): 642-648.
129. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 1997; 46(1): 67-70.
130. Mack C, Wilson J, Athanacio J, et al. Pharmacological actions of the peptide normone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol 2007; 293(5): 1855-1863. (Pubitemid 350085661)
131. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992; 339(8802): 1179-1180.
132. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther 2002; 4(2): 175-189. (Pubitemid 34663480)
133. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002; 34(9): 504-508. (Pubitemid 35192237)
134. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 1997; 14(7): 547-555. (Pubitemid 27298814)
135. Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 1997; 46(4): 632-636. (Pubitemid 27143379)
136. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25(4): 724-730. (Pubitemid 41071194)
137. Kellmeyer TA, Kesty NC, Wang Y, Frias JP, Fineman MS. Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes. J Clin Pharmacol 2007; 47(7): 798-805.
138. Wörle HJ, Albrecht M, Linke R, et al. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am J Physiol Endocrinol Metab 2008; 294(1): E103-E109.
139. Kong MF, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 1997; 40(1): 82-88. (Pubitemid 27035714)
140. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004; 286(6): E882-E890. (Pubitemid 38668808)
141. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25(6): 781-792. (Pubitemid 32601369)
142. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38(6): 720-725.
143. Schirra J, Houck P, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antropyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000; 46(5): 622-631. (Pubitemid 30305778)
144. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144(12): 5145-5148.
145. Schirra J, Leicht P, Hildebrand P, et al. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol 1998; 156(1): 177-186. (Pubitemid 28049877)
146. Schirra J, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002; 50(3): 341-348. (Pubitemid 34161049)
147. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in
148. Horowitz M, Nauck MA. To be or not to be - an incretin or enterogastrone? Gut 2006; 55(2): 148-150. (Pubitemid 43117267)
149. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Cersosimo E Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008; 294(5): E846-E852.
150. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287(2): E199-E206. (Pubitemid 38943883)
151. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86(8): 3717-3723. (Pubitemid 32755966)
152. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90(11): 5991-5997. (Pubitemid 41606516)
153. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129.
154. Drucker DJ, Buse JB, Taylor K, et al.; for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372(9645): 1240-1250.
155. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25(8): 1398-1404. (Pubitemid 41071152)
156. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45(2): 195-202. (Pubitemid 34208381)
157. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; Mar 16 [Epub ahead of print].
158. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32(1): 84-90.
159. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373(9662): 473-481.
160. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27(8): 1915-1921. (Pubitemid 38989232)
161. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27(6): 1335-1342. (Pubitemid 38679980)
162. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51(2): 424-429. (Pubitemid 34764798)
163. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53(5): 1187-1194. (Pubitemid 38569002)
164. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30(6): 1608-1610. (Pubitemid 46871185)